Welcome to our dedicated page for Prestige Consumer Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prestige Consumer Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prestige Consumer Healthcare's regulatory disclosures and financial reporting.
Prestige Consumer Healthcare Inc. reports a leadership change in its operations function. On August 10, 2026, Jeffrey Zerillo informed the company of his decision to retire from his role as Senior Vice President, Operations and from all other positions he holds with the company, effective August 14, 2026.
The company’s common stock, par value $0.01 per share, continues to be listed on the New York Stock Exchange under the symbol PBH. The report is signed by Christine Sacco, Chief Financial Officer & Chief Operating Officer.
Prestige Consumer Healthcare Inc. reported total revenues of 265,710 (stated in thousands of dollars) for the three months ended June 30, 2026, up 6.5% from 249,530. Growth came mainly from North American OTC Healthcare, especially Wellness, Sleep & Other and Gastrointestinal categories, but gross profit fell 3.0% to 136,188 (in thousands). Net income declined to 29,177 (in thousands), with basic and diluted EPS of $0.61 versus $0.96 and $0.95 a year earlier, driven by lower margins and higher expenses.
On June 12, 2026, the company completed the $1,045.0 million cash acquisition of the OTC Wellness Business, including Breathe Right and other brands, funded by a new $1,045,000 (in thousands) Term Loan Credit Agreement maturing in 2033. This added 31,126 (in thousands) of inventories, 948,370 (in thousands) of intangible assets and 65,504 (in thousands) of goodwill, lifting total goodwill to 650,795 (in thousands) and intangible assets, net, to 3,243,358 (in thousands). Total long-term debt including current portion rose to 2,045,000 (in thousands), while cash and cash equivalents increased to 89,127 (in thousands), supported by 70,788 (in thousands) of operating cash flow.
Subsequent to quarter-end, Prestige closed the approximately $150.0 million LaCorium Health acquisition, funded partly by an additional $95.0 million term loan draw, and issued $400.0 million of 6.25% senior notes due 2034 to redeem all $400.0 million of its 5.125% 2019 Senior Notes. The company highlights ongoing supply-chain pressures, particularly for sterile eye care products, and significant customer and supplier concentration, with Walmart and Amazon representing 19% and 16% of gross revenues, respectively, and one key supplier accounting for 22%.
Prestige Consumer Healthcare reported first-quarter fiscal 2027 revenue of $265.7 million, up 6.5% from $249.5 million a year earlier, with organic sales growth of 3.2%. The Breathe Right acquisition contributed about $5.9 million of revenue, with strong performance in Gastrointestinal and Dermatological categories.
GAAP net income was $29.2 million with diluted EPS of $0.61, down from $0.95, reflecting acquisition, integration and Pillar5 remediation costs and higher interest expense. On a non-GAAP basis, adjusted net income was $46.5 million and adjusted diluted EPS $0.98, up from $0.95. Adjusted EBITDA reached $84.1 million and adjusted EBITDA margin was 31.6%.
Operating cash flow was $70.8 million, and adjusted free cash flow rose to a record $83.7 million. Net debt was about $2.0 billion after funding the Breathe Right and related OTC brands acquisition with a $1.045 billion term loan. Management closed the Breathe Right and LaCorium deals, expects the acquisitions to add nearly 20% to the revenue base, and raised fiscal 2027 guidance to revenue of $1.29–$1.315 billion and adjusted diluted EPS of $4.55–$4.65, with adjusted free cash flow of at least $270 million.
ZIER DAWN M. reported acquisition or exercise transactions in this Form 4 filing.
Prestige Consumer Healthcare Inc. reported that director Dawn M. Zier received a grant of 2,981 restricted stock units, calculated as $155,000 divided by the $52.00 closing share price on August 4, 2026, under the director compensation program. The RSUs vest on the first anniversary of grant and will be settled in one share of common stock per unit after vesting upon the earliest of the director’s death, separation, or a change in control, and her directly held common stock position is now 19,514 shares.
Kelly John F. reported acquisition or exercise transactions in this Form 4 filing.
Prestige Consumer Healthcare director John F. Kelly received a grant of 2,981 restricted stock units on August 4, 2026, valued at $155,000 using a $52.00 share price under the director compensation program. These RSUs vest on the first anniversary of grant and are settled in common stock upon the earliest of his death, separation, or a change in control, after which his reported direct holdings total 7,832 shares.
DArecca James reported acquisition or exercise transactions in this Form 4 filing.
Prestige Consumer Healthcare Inc. director James DArecca received a grant of 2,981 restricted stock units, valued at $155,000 based on a $52.00 share price, under the director compensation program. The units vest after one year and will be settled in common stock upon specified separation, death, or change-in-control events, bringing his reported holdings to 9,572 shares.
Prestige Consumer Healthcare Inc. reported that director Celeste A. Clark acquired an equity award of 2,981 restricted stock units, valued at $155,000 based on a $52.00 closing share price on August 4, 2026, under the director compensation program. The units vest on the first anniversary of grant and will be settled in one share of common stock per vested unit upon the earliest of Clark’s death, separation, or a change in control. Following this award, 16,511 shares of common stock are reported as directly owned.
BYOM JOHN E reported acquisition or exercise transactions in this Form 4 filing.
Prestige Consumer Healthcare Inc. director John E. Byom received a grant of 2,981 restricted stock units, valued at $155,000 based on a $52.00 closing price on August 4, 2026, under the director compensation program. The RSUs vest after one year, and his direct common stock holdings are now 54,575 shares.
Prestige Consumer Healthcare Inc., through its wholly owned subsidiary Prestige Brands, Inc., issued $400.0 million of 6.250% senior unsecured notes due July 15, 2034. Interest is payable semiannually on January 15 and July 15, beginning January 15, 2027. The notes are guaranteed on a senior unsecured basis by the company and certain existing and future domestic restricted subsidiaries.
The notes are redeemable before and after July 15, 2029 on terms set in the indenture, including optional redemptions with a make-whole premium and the ability to redeem up to 40% using proceeds of certain equity offerings. Upon a defined Change of Control, holders must be offered repurchase at 101% of principal plus accrued interest. The indenture includes customary covenants limiting additional indebtedness, restricted payments, liens, asset sales, mergers and affiliate transactions, subject to exceptions.
Prestige Consumer Healthcare Inc. filed an amended Form 8-K/A to update disclosure around its acquisition of the OTC Wellness Business from Foundation Consumer Brands. The amendment primarily removes an inadvertently included auditor review report and keeps prior 8-K and 8-K/A information otherwise unchanged.
Exhibit 99.2 provides unaudited condensed combined financials for the OTC Wellness Business for the three months ended March 31, 2026. Net sales were $51.7 million versus $50.5 million a year earlier, with net income of $12.6 million compared with $14.8 million.